• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld Asia

BioWorld Asia

Nov. 2, 2016

View Archived Issues

Worm protein shown to be effective against asthma

An Australian study has identified a protein secreted by parasitic hookworms that suppresses asthma in mice, with in vitro tests on cells from asthmatics indicating that the protein is a promising candidate for development of new anti-inflammatory treatments. Read More

New funding mechanism could create needed life sciences ecosystem

MELBOURNE, Australia – The Australian government is injecting more funding into its life sciences sector to help it become more globally competitive in commercializing products. Read More

China Resources Hong Kong IPO rakes in $1.8B

HONG KONG – Shares of China Resources Pharmaceutical Group Ltd. (HK:3320) sank in their trading debut on Oct. 28 after raising about $1.8 billion in Hong Kong, making it the largest IPO from a drugmaker in Asia this year. Read More

India's TB drug R&D in need of more funding, innovation

NEW DELHI – While India's tuberculosis (TB) drug industry is generally geared to meet the country's enormous TB burden, which is mainly due to poor patient compliance and multidrug resistance, it is hampered by limited access to high-risk funding and hurdles in regulatory approval. Read More

Post IPO, Noxopharm heading to clinic with lead candidate idronoxil

PERTH, Australia – After completing its IPO in July, Sydney-based Noxopharm Pty Ltd. expects to have the first three clinical trials of its lead compound up and running in the first quarter of 2017. Read More

Other news to note

Novogen Ltd., of Sydney, has acquired Glioblast Pty Ltd., a privately held, neuro-oncology-focused Australian biotechnology company, to support development of GDC-0084, a small-molecule inhibitor of the phosphoinositide-3-kinase (PI3K) pathway newly licensed from Basel, Switzerland-based Roche AG's Genentech Inc. Read More

CFDA reforms deepen to accelerate innovation

SUZHOU, China – Ruyi He, chief scientist of the CFDA and the Centre for Drug Evaluation (CDE), outlined the government's commitment to streamline and speed up the review process for innovative drugs, sharing support for more dynamic communication between reviewers and sponsors. He joined the CFDA/CDE in July after more than a decade with the U.S. FDA. Read More

Astellas laudin' claudin: $1.4B Ganymed buy after ASCO sees phase II 'Xtandi' and deliver

It was hardly rocket science that Jupiter moon-named Ganymed Pharmaceuticals AG's claudin 18.2-targeting antibody – the one that created so much buzz at this year's American Society of Clinical Oncology (ASCO) meeting – would draw big pharma's top cancer players to the table. And Tokyo-based winner Astellas Pharma Inc.'s potential $1.4 billion takeover, with €422 million (US$461.3 million) up front plus another €860 million if progress milestones are met, gets not only the IMAB362 antibody but also Claudetect 18.2, an in vitro diagnostic for the biomarkers in patients most likely to be helped. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe